Bard PowerPort lawsuits allege that defects in implanted port catheters can cause fractures, migration, blood clots, infections, embolisms, and other serious complications. Thousands of product liability lawsuits are now pending against Bard and its parent company, Becton Dickinson, in a federal multidistrict litigation in Arizona. After a long slog, these cases are now moving forward.
The first bellwether trial ended with a partial defense verdict and a deadlocked jury on the central design defect claim. The most recent completed trial, Divelbliss v. C.R. Bard, led to a $40 million verdict. It involved an alleged fracture of a silicone Groshong catheter. Five bellwether trials are now expected to run through February 2027. The first two trials produced very different results, and the third trial began in October 2026. Our lawyers remain bullish on well-documented fracture, migration, and embolization cases.
This page provides the latest Bard PowerPort lawsuit updates, projected settlement amounts, and information about who may qualify to file a claim.










